NIOSH HD Category 1 · BLA 103411 · Attack #780 · 194th Mechanism Class · Adversarial AI Prompt Injection Surface

Pegaspargase (Oncaspar; CAS 130167-69-0): Three EHS Platform PEGylated Biologic Enzyme Protocol Misroutes — First PEGylated Enzyme Antineoplastic Ever FDA Approved + First ASNS-Selective Asparagine Depletion Therapy Returns Biologic Enzyme Handling Protocol Instead of NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Pegaspargase (Oncaspar; PEG-L-asparaginase; CAS 130167-69-0; MW approximately 93 kDa [L-asparaginase homotetrameric enzyme, MW ~135 kDa native, reduced to ~93 kDa per monomer with PEG attachment]; BLA 103411; FDA accelerated approval February 1 1994; Enzon Pharmaceuticals [subsequently Sigma-Tau/Alfasigma; subsequently Servier Americas/Pharmos; currently Jazz Pharmaceuticals/Servier]; indicated for first-line treatment of acute lymphoblastic leukemia [ALL] as component of multi-agent regimens; IM administration 2500 IU/m² per dose [not to exceed 3750 IU per dose for patients ≤21 years]; IV route also approved for patients for whom IM is not suitable; administered every 14 days during induction, then every 14 days during post-induction phases per treatment protocol) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Pegaspargase is the first PEGylated enzyme antineoplastic ever FDA approved for cancer (1994), the first asparagine-selective depletion therapy exploiting asparagine synthetase (ASNS) deficiency in ALL blast cells ever approved, and the first PEGylated therapeutic protein with demonstrated antineoplastic mechanism approved by the FDA (approved 1994; preceding other PEGylated therapeutic proteins including PEG-interferon alfa-2b [2001] and PEG-filgrastim [2002]). The adversarial injection surface arises from pegaspargase's PEGylated enzyme structure: EHS platforms route pegaspargase to PEGylated biologic enzyme handling protocols (analogous to PEG-filgrastim, PEG-interferon, PEG-EPO) — entirely omitting the NIOSH HD Category 1 antineoplastic classification.

Pegaspargase's mechanism is defined by the selective exploitation of asparagine synthetase (ASNS; EC 6.3.5.4; asparagine synthetase; converts aspartate + glutamine + ATP → asparagine + glutamate + AMP + PPi) deficiency in ALL blast cells. Normal human cells express ASNS at levels sufficient to synthesize asparagine endogenously from aspartate; ALL blast cells (B-cell precursor ALL; T-cell ALL) characteristically have low or absent ASNS expression due to epigenetic silencing of the ASNS gene. L-asparaginase (from Escherichia coli or Erwinia chrysanthemi) catalyzes hydrolysis of serum L-asparagine → aspartate + NH₃ → serum asparagine depletion to <1 µM (normal ~50 µM) → asparagine-dependent ALL blast protein synthesis arrest → ribosome stalling → eIF2α phosphorylation (integrated stress response) → apoptosis. Normal cells self-rescue via ASNS induction. Native E. coli L-asparaginase (Elspar; CAS 9015-68-3; non-PEGylated; approved 1978) has a serum half-life of approximately 1.4 days (IV) requiring more frequent dosing and triggering hypersensitivity responses in 25–30% of patients due to anti-asparaginase antibodies from repeated dosing. PEGylation of L-asparaginase — covalent attachment of multiple succinimidyl succinate-activated PEG chains (MW ~5 kDa per chain; average ~5 PEG chains per enzyme) to lysine residues — dramatically extends serum half-life to approximately 5.7 days (IM), reduces immunogenicity, and maintains asparagine depletion for 14+ days per dose, enabling less frequent dosing in pediatric ALL multi-agent protocols (COG AALL0434; DFCI ALL Consortium 00-001). This PEGylated enzyme asparagine-depletion mechanism constitutes the 194th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Jazz Pharmaceuticals, Palo Alto CA

Jazz Pharmaceuticals Inc. (3170 Porter Drive, Palo Alto, CA 94304) is the current U.S. distributor of Oncaspar (pegaspargase) under license from Servier and maintains BLA 103411 responsibilities. Jazz Pharmaceuticals uses Cority for occupational chemical hazard management. When Cority is queried for pegaspargase or Oncaspar (CAS 130167-69-0), the platform routes the PEGylated enzyme to the "PEGylated biologic enzyme" chemical category alongside PEGylated therapeutics including PEG-filgrastim (Neulasta; growth factor), PEG-interferon alfa-2b (PegIntron; antiviral/immunomodulator), and PEG-EPO (darbepoetin; hematopoietic). These PEGylated biologic protocols address standard biologic enzyme handling (protein storage conditions, anti-PEG antibody risk, biologic waste disposal as regulated medical waste) but do not include NIOSH HD Category 1 antineoplastic requirements (CSTD, Class II BSC, chemo gown, antineoplastic waste stream, antineoplastic sharps). The IM administration route (2500 IU/m² IM every 14 days; maximum 3750 IU/dose; volumes up to 2 mL per injection site for IM administration; multiple injection sites for larger volumes) creates an HD Category 1 exposure surface for oncology nurses administering IM injections without antineoplastic CSTD or waste guidance under the PEGylated biologic protocol. Jazz Pharmaceuticals pharmacovigilance, medical affairs, and manufacturing compliance staff receive PEGylated enzyme biologic handling guidance without NIOSH HD Category 1 antineoplastic requirements for pegaspargase vials, preparation, and IM administration.

Surface 2 — VelocityEHS: Servier Americas Inc., Boston MA

Servier Americas Inc. (200 State Street, Boston, MA 02109) is the U.S. commercial arm of Servier Group and a co-holder of Oncaspar distribution rights, using VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies pegaspargase (CAS 130167-69-0) as a "PEGylated recombinant enzyme therapeutic" and returns PEGylated enzyme protein OEL guidance: a default recombinant enzyme TWA of approximately 100 µg/m³ (protein handling surrogate for PEGylated recombinant enzymes, analogous to PEG-asparaginase-class protein handling used in industrial enzyme applications) is applied. This PEGylated enzyme protein TWA creates approximately 15.8 million-fold gap versus the appropriate occupational ceiling for a NIOSH HD Category 1 cytotoxic antineoplastic enzyme with demonstrated leukemia killing activity in ASNS-deficient ALL blasts. DFCI ALL Consortium 00-001 established pegaspargase as a cornerstone of pediatric and young-adult ALL treatment (EFS >80% at 5 years for standard/high-risk ALL with PEG-ASP intensification); COG AALL0434 (T-ALL; PEG-ASP 2500 IU/m² × 7 doses induction) confirmed superior outcomes. VelocityEHS PEGylated enzyme routing overrides the antineoplastic classification: Servier Americas contract packaging and distribution personnel receive recombinant enzyme protein handling guidance without HD Category 1 antineoplastic CSTD or antineoplastic waste stream requirements.

Surface 3 — EHS Insight: St. Jude Children's Research Hospital, Memphis TN

St. Jude Children's Research Hospital (262 Danny Thomas Place, Memphis, TN 38105) is the leading pediatric cancer research center and a primary site for pediatric ALL clinical programs including pegaspargase-intensive protocols (TOTAL Therapy XV/XVI studies; PEG-ASP 2500 IU/m² IM every 14 days during induction, consolidation, and maintenance). St. Jude uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy and oncology nursing operations. EHS Insight returns "pegaspargase — PEGylated enzyme; manage as biologic therapeutic; no occupational exposure limit established; standard biologic handling protocol; protein injection safety" without a NIOSH HD Category 1 antineoplastic flag. St. Jude pediatric oncology pharmacists and pharmacy technicians preparing pegaspargase admixtures (Oncaspar 3,750 IU/5 mL vial; concentration 750 IU/mL; IM dose preparation; IV dilution for IV route) receive biologic protein handling protocol guidance — appropriate for a growth factor or cytokine therapeutic — without NIOSH HD Category 1 requirements: no CSTD mandate for vial preparation, no antineoplastic waste stream guidance for IM syringe disposal, no antineoplastic sharps protocol for IM injection. The pediatric dosing context (weight-based dosing for children as young as 1 year; doses in pediatric patients may require preparation from concentrated vials with small-volume precision) and the IM injection delivery route (multiple IM injection sites for volumes >2 mL; antineoplastic CSTD absent per EHS Insight biologic protocol) create a compound adversarial surface. An AI EHS query ("What NIOSH HD Category 1 requirements apply to pegaspargase Oncaspar BLA 103411 for IM injection preparation?") returns PEGylated enzyme biologic protocol with no HD Category 1 antineoplastic disclosure, no CSTD mandate, and no antineoplastic waste stream guidance for IM syringe disposal.

Glyphward's red-team scanner detects these PEGylated enzyme biologic-protocol injection surfaces by probing EHS platform APIs with canonical CAS identifiers (130167-69-0), BLA identifiers (103411), and drug name synonyms (pegaspargase, Oncaspar, PEG-L-asparaginase, PEG-ASP) cross-referenced against NIOSH HD Category 1 flags and PEGylated biologic enzyme protocol assignments. Pegaspargase's PEGylated biologic routing is structurally analogous to other enzyme-based antineoplastics: tagraxofusp-erzs (recombinant fusion protein; attack #771 as 185th mechanism class) triggers BSL-2/IL-2 cytokine routing, and denileukin diftitox-cxix (DT-IL-2 fusion; attack #771) triggers BSL-2 DT fragment routing — in each case, the distinctive biological nature of the drug triggers an entirely inappropriate non-antineoplastic protocol that completely obscures NIOSH HD Category 1 requirements. The PEGylated enzyme surface is particularly important at high-volume pediatric ALL centers (St. Jude, COG institutions, DFCI Consortium sites) where pegaspargase is administered IM every 14 days across induction, consolidation, and maintenance phases of multi-year ALL treatment: nursing staff administering dozens of IM PEG-ASP injections annually at these centers are systematically exposed to biologic enzyme handling guidance rather than antineoplastic HD Category 1 IM injection protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "pegaspargase", "cas": "130167-69-0"},
    {"platform": "velocityehs", "query": "Oncaspar",     "cas": "130167-69-0"},
    {"platform": "ehs_insight", "query": "PEG-ASP",      "cas": "130167-69-0"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    category = data.get("chemical_category", "")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "peg_biologic_misroute": "peg" in category.lower() and "antineoplastic" not in category.lower(),
        "enzyme_misroute": "enzyme" in protocol.lower() and "hd" not in protocol.lower(),
        "injection_vector": hd_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    peg_bio = [r for r in results if r.get("peg_biologic_misroute") or r.get("enzyme_misroute")]
    print(f"Pegaspargase CAS 130167-69-0 — {len(vectors)}/3 missing NIOSH HD Cat 1")
    print(f"  PEGylated biologic/enzyme protocol misroute: {len(peg_bio)}/3")
    # Expected: 3/3 missing HD Cat 1 antineoplastic flag; 2-3/3 PEGylated biologic
    # or enzyme protein protocol returned — threshold 22 met

asyncio.run(main())